文章摘要
姬 峰,张 鹏,亓 梅,沈 宁,韩其政.经鼻高流量氧疗联合参芪扶正注射液对COPD合并Ⅱ型呼吸衰竭患者动脉血气、炎性因子及免疫功能的影响[J].,2021,(17):3300-3304
经鼻高流量氧疗联合参芪扶正注射液对COPD合并Ⅱ型呼吸衰竭患者动脉血气、炎性因子及免疫功能的影响
Effects of Transnasal High Flow Oxygen Therapy Combined with Shenqifuzheng Injection on Arterial Blood Gas, Inflammatory Factors and Immune Function in Patients with COPD and Type Ⅱ Respiratory Failure
投稿时间:2020-12-04  修订日期:2020-12-28
DOI:10.13241/j.cnki.pmb.2021.17.022
中文关键词: 经鼻高流量氧疗  参芪扶正注射液  慢性阻塞性肺病  Ⅱ型呼吸衰竭  免疫功能  炎性因子  动脉血气
英文关键词: Transnasal high flow oxygen therapy  Shenqifuzheng injection  Chronic obstructive pulmonary disease  Type Ⅱ respiratory failure  Immune function  Inflammatory factors  Arterial blood gas
基金项目:山东省中医药科技发展计划项目(2019-0164);济南市科技计划项目(201805014)
作者单位E-mail
姬 峰 山东大学附属省耳鼻喉医院/山东省立医院西院呼吸与危重症医学科 山东 济南 250022 sdjf1979@163.com 
张 鹏 山东大学附属省耳鼻喉医院/山东省立医院西院呼吸与危重症医学科 山东 济南 250022  
亓 梅 山东大学附属省耳鼻喉医院/山东省立医院西院呼吸与危重症医学科 山东 济南 250022  
沈 宁 山东中医药大学附属医院肺病科 山东 济南 250000  
韩其政 山东大学附属省耳鼻喉医院/山东省立医院西院呼吸与危重症医学科 山东 济南 250022  
摘要点击次数: 560
全文下载次数: 288
中文摘要:
      摘要 目的:探讨经鼻高流量氧疗联合参芪扶正注射液对慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭患者动脉血气、炎性因子及免疫功能的影响。方法:选择2017年5月-2019年12月我院收治的COPD合并Ⅱ型呼吸衰竭患者104例,随机分为研究组和对照组,每组52例。两组患者均给予了基础治疗,对照组采用经鼻高流量氧疗治疗,研究组采用经鼻高流量氧疗联合参芪扶正注射液治疗。比较两组临床疗效、不良反应发生情况及治疗前后的动脉血气指标[动脉血PH值、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、血氧饱和度(SaO2)],血清炎性因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]水平,外周血CD4+T细胞、CD8+T细胞水平及CD4+/ CD8+值、免疫球蛋白A(IgA)、IgM、IgG水平。结果:研究组总有效率为92.31%(48/52),显著高于对照组78.85%(40/52)(P<0.05)。治疗后两组患者动脉血pH值、PaO2、SaO2、CD4+T细胞、CD4+/CD8+、IgA、IgM、IgG显著升高,PaCO2、IL-6、TNF-α、CRP、CD8+显著降低(P<0.05),研究组患者动脉血pH值、PaO2、SaO2、CD4+T细胞、CD4+/CD8+值、IgA、IgM、IgG显著高于对照组,PaCO2、IL-6、TNF-α、CRP、CD8+T细胞显著低于对照组(P<0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论:经鼻高流量氧疗联合参芪扶正注射液治疗可纠正COPD合并II型呼吸衰竭患者的动脉血气指标,改善免疫功能,缓解机体炎症反应。
英文摘要:
      ABSTRACT Objective: To investigate the effects of transnasal high flow oxygen therapy combined with Shenqifuzheng Injection on arterial blood gas, inflammatory factors and immune function in patients with chronic obstructive pulmonary disease (COPD) and type II respiratory failure. Methods: 104 COPD patients with type II respiratory failure admitted to our hospital from May 2017 to December 2019 were selected, they were randomly divided into study group and control group with 52 cases in each group. Both groups were given basic treatment, the control group was treated by transnasal high flow oxygen therapy, the study group was treated by transnasal high flow oxygen therapy combined with Shenqifuzheng injection. The clinical effects, adverse reactions, arterial blood gas indexes [pH value of arterial blood, arterial oxygen partial pressure(PaO2), arterial partial pressure of carbon dioxide(PaCO2), blood oxygen saturation (SaO2)], serum inflammatory factors [interleukin-6(IL-6), tumor necrosis factor -α(TNF-α), C-reactive protein (CRP)], Levels of CD4+T cells, CD8+T cells and CD4+/CD8+ values in peripheral blood, immunoglobulin A (IGA), IgM, IgG were compared. Results: The total effective rate of the study group was 92.31% (48/52), significantly higher than 78.85% (40/52) of the control group (P<0.05). After treatment, the pH value, PaO2, SaO2, CD4+T cells, CD4+/CD8+, IgA, IgM and IgG of arterial blood in the two groups increased significantly, while PaCO2, IL-6, TNF-α, CRP and CD8+ decreased significantly(P<0.05). The pH value, PaO2, SaO2, CD4+T cell、CD4+/CD8+ value, IgA, IgM, IgG in the study group were higher than those of the control group, PaCO2, IL-6、TNF-α, CRP, CD8+T cell were lower than those of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Transnasal high flow oxygen therapy combined with Shenqifuzheng injection can correct the arterial blood gas index of COPD patients with type II respiratory failure, improve the immune function and alleviate the inflammatory response of the body.
查看全文   查看/发表评论  下载PDF阅读器
关闭